Get access to our best features

Get access to our best features

Published 2 months ago

Moderna CEO calls 2023 ‘difficult year': Here's why 2024 could bring new hope

Summary by Ground News

Moderna reported $6.1 billion in vaccine sales for the 2023 fiscal year during its fourth-quarter earnings. That number excludes roughly $600 million in deferred revenue related to Gavi, the Vaccine Alliance. Moderna adjusted its 2023 vaccine-sales outlook to the lower end of its previous forecast last quarter.

0 Articles

0 Articles

All

Left

Center

Right

The Business Journals

Moderna CEO calls 2023 ‘difficult year.’ Here's why 2024 could bring new hope.

After barely beating its 2023 vaccine-sales outlook, which Moderna had previously adjusted down, the Cambridge company is gearing up for a future beyond Covid-19 vaccines.

2 months ago·United States

Read Full Article

Moderna CEO calls 2023 ‘difficult year': Here's why 2024 could bring new hope

2023 was a ‘difficult year’ for Moderna. Here's what caused it.

2 months ago·Boston, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left1Leaning Right0Center1Last Updated2 months agoBias Distribution

50% Left, 50% Center

Bias Distribution

50% of the sources lean Left, 50% of the sources are Center

50% Center

NBC Boston

The Business Journals

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.